| Non-Hodgkin Lymphoma (NHL) |
1 |
1 |
| Biologic Therapy |
0 |
0.98 |
| CAR-T |
0 |
0.68 |
| Lymphoma |
0 |
0.53 |
| Antineoplastic Drug |
0 |
0.42 |
| B-Cell Lymphoma |
0 |
0.99 |
| Follicular Lymphoma |
0 |
0.41 |
| Cancer |
0 |
0.35 |
| Genomic Medicine |
0 |
0.27 |
| California |
0 |
0.18 |
| Chemotherapy |
0 |
0.18 |
| Clinical Research |
0 |
0.18 |
| Healthcare and Medical Technology |
0 |
0.18 |
| Monoclonal Antibody |
0 |
0.18 |
| Multiple Myeloma |
0 |
0.12 |
| Refractory |
0 |
0.12 |
| Remission |
0 |
0.12 |
| Revenue and Practice Management |
0 |
0.1 |
| Stem Cell Research and Therapy |
0 |
0.1 |
| Patient Safety |
0 |
0.09 |
| Adverse Effects |
0 |
0.06 |
| Antigens |
0 |
0.06 |
| Canada |
0 |
0.06 |
| Genetics |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Immunotherapy |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Prognosis |
0 |
0.06 |
| Social Determinants of Health |
0 |
0.06 |
| Socioeconomics |
0 |
0.06 |
| Transplantation |
0 |
0.06 |